Crenolanib
- Generic Name
- Crenolanib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C26H29N5O2
- CAS Number
- 670220-88-9
- Unique Ingredient Identifier
- LQF7I567TQ
- Background
Crenolanib is under investigation for the treatment of Diffuse Intrinsic Pontine Glioma and Progressive or Refractory High-Grade Glioma.
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Crenolanib With Fludarabine and Cytarabine in Pediatric Patients With Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2017-10-27
- Last Posted Date
- 2019-01-10
- Lead Sponsor
- Arog Pharmaceuticals, Inc.
- Registration Number
- NCT03324243
Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML
- Conditions
- Interventions
- First Posted Date
- 2017-08-23
- Last Posted Date
- 2020-05-22
- Lead Sponsor
- Arog Pharmaceuticals, Inc.
- Target Recruit Count
- 510
- Registration Number
- NCT03258931
- Locations
- 🇺🇸
John Theurer Cancer Center at Hackensack UMC, Hackensack, New Jersey, United States
🇺🇸Cornell University, New York, New York, United States
🇺🇸Oregon Health and Science University, Portland, Oregon, United States
Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML
- First Posted Date
- 2017-08-15
- Last Posted Date
- 2021-04-30
- Lead Sponsor
- Arog Pharmaceuticals, Inc.
- Target Recruit Count
- 322
- Registration Number
- NCT03250338
- Locations
- 🇺🇸
Kansas University, Kansas City, Kansas, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
🇨🇦University of Alberta, Edmonton, Alberta, Canada
Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2017-06-21
- Last Posted Date
- 2020-07-20
- Lead Sponsor
- Arog Pharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT03193918
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST
- First Posted Date
- 2016-07-28
- Last Posted Date
- 2021-01-22
- Lead Sponsor
- Arog Pharmaceuticals, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT02847429
- Locations
- 🇺🇸
Sarcoma Oncology Center, Santa Monica, California, United States
🇺🇸Duke Cancer Institute, Durham, North Carolina, United States
🇺🇸Oregon Health and Science University, Portland, Oregon, United States
Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification
- First Posted Date
- 2015-12-10
- Last Posted Date
- 2020-07-20
- Lead Sponsor
- Arog Pharmaceuticals, Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT02626364
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML
- First Posted Date
- 2015-12-10
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- Arog Pharmaceuticals, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT02626338
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸Houston Methodist, Houston, Texas, United States
🇺🇸University of Arkansas, Little Rock, Arkansas, United States
Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 Mutations
- Conditions
- Interventions
- First Posted Date
- 2014-11-21
- Last Posted Date
- 2021-10-06
- Lead Sponsor
- University of Ulm
- Target Recruit Count
- 9
- Registration Number
- NCT02298166
- Locations
- 🇩🇪
Ulm University Hospital, Ulm, Germany
A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations
- Conditions
- Interventions
- First Posted Date
- 2014-11-05
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Arog Pharmaceuticals, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT02283177
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2014-10-21
- Last Posted Date
- 2017-10-03
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT02270788
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.